HIV DNA persists in hepatocytes in people with HIV-hepatitis B co-infection on antiretroviral therapy
Jennifer M. Zerbato(The University of Melbourne), Sharon R. Lewin(The Royal Melbourne Hospital), Hugh S. Mason(Arizona State University), Claire Deléage(Leidos (United States)), Anchalee Avihingsanon(Chulalongkorn University), Surekha Tennakoon(The University of Melbourne), Angela D. M. Kashuba(University of North Carolina at Chapel Hill), Peter Revill(Queensland University of Technology), Sabine Braat(The University of Melbourne), Kasha P. Singh(The Royal Melbourne Hospital), Ajantha Rhodes(The University of Melbourne), Jennifer Audsley(The University of Melbourne), Ashanti Dantanarayana(The University of Melbourne), Carolin Tumpach(The University of Melbourne), Michael Roche(The University of Melbourne), Mackenzie L. Cottrell(University of North Carolina at Chapel Hill), Elias P. Rosen(University of North Carolina at Chapel Hill), Megan Crane(Peter MacCallum Cancer Centre), David J. Price(The University of Melbourne), Wei Zhao(The University of Melbourne)
Cited by 30
Related Papers
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy
|Nature|2012|1.2k
Immune checkpoint blockade in infectious diseases
|Nature reviews. Immunology|2017|571
Activation of HIV Transcription with Short-Course Vorinostat in HIV-Infected Patients on Suppressive Antiretroviral Therapy
|PLoS Pathogens|2014|509
Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021
|Nature Medicine|2021|367
Penetration of Tenofovir and Emtricitabine in Mucosal Tissues: Implications for Prevention of HIV-1 Transmission
|Science Translational Medicine|2011|350